Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Density-dependent resistance protects Legionella pneumophila from its own antimicrobial metabolite, HGA.

Levin TC, Goldspiel BP, Malik HS.

Elife. 2019 May 28;8. pii: e46086. doi: 10.7554/eLife.46086.

2.

Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum.

Parker VER, Keppler-Noreuil KM, Faivre L, Luu M, Oden NL, De Silva L, Sapp JC, Andrews K, Bardou M, Chen KY, Darling TN, Gautier E, Goldspiel BR, Hadj-Rabia S, Harris J, Kounidas G, Kumar P, Lindhurst MJ, Loffroy R, Martin L, Phan A, Rother KI, Widemann BC, Wolters PL, Coubes C, Pinson L, Willems M, Vincent-Delorme C; PROMISE Working Group, Vabres P, Semple RK, Biesecker LG.

Genet Med. 2019 May;21(5):1189-1198. doi: 10.1038/s41436-018-0297-9. Epub 2018 Oct 1.

3.

Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.

Phillips EJ, Sukasem C, Whirl-Carrillo M, Müller DJ, Dunnenberger HM, Chantratita W, Goldspiel B, Chen YT, Carleton BC, George AL Jr, Mushiroda T, Klein T, Gammal RS, Pirmohamed M.

Clin Pharmacol Ther. 2018 Apr;103(4):574-581. doi: 10.1002/cpt.1004. Epub 2018 Feb 2.

4.

Pharmacogenomics Implementation at the National Institutes of Health Clinical Center.

Sissung TM, McKeeby JW, Patel J, Lertora JJ, Kumar P, Flegel WA, Adams SD, Eckes EJ, Mickey F, Plona TM, Mellot SD, Baugher RN, Wu X, Soppet DR, Barcus ME, Datta V, Pike KM, DiPatrizio G, Figg WD, Goldspiel BR.

J Clin Pharmacol. 2017 Oct;57 Suppl 10:S67-S77. doi: 10.1002/jcph.993. Review.

5.

Safety, pharmacokinetics and sialic acid production after oral administration of N-acetylmannosamine (ManNAc) to subjects with GNE myopathy.

Xu X, Wang AQ, Latham LL, Celeste F, Ciccone C, Malicdan MC, Goldspiel B, Terse P, Cradock J, Yang N, Yorke S, McKew JC, Gahl WA, Huizing M, Carrillo N.

Mol Genet Metab. 2017 Sep;122(1-2):126-134. doi: 10.1016/j.ymgme.2017.04.010. Epub 2017 Apr 26.

6.

Stability of tacrolimus solutions in polyolefin containers.

Lee JH, Goldspiel BR, Ryu S, Potti GK.

Am J Health Syst Pharm. 2016 Feb 1;73(3):137-42. doi: 10.2146/ajhp150264.

PMID:
26796907
7.

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update.

Saito Y, Stamp LK, Caudle KE, Hershfield MS, McDonagh EM, Callaghan JT, Tassaneeyakul W, Mushiroda T, Kamatani N, Goldspiel BR, Phillips EJ, Klein TE, Lee MT; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2016 Jan;99(1):36-7. doi: 10.1002/cpt.161. Epub 2015 Jul 16.

8.

ASHP guidelines on preventing medication errors with chemotherapy and biotherapy.

Goldspiel B, Hoffman JM, Griffith NL, Goodin S, DeChristoforo R, Montello CM, Chase JL, Bartel S, Patel JT.

Am J Health Syst Pharm. 2015 Apr 15;72(8):e6-e35. doi: 10.2146/sp150001. No abstract available.

PMID:
25825193
9.

Preventing chemotherapy errors: updating guidelines to meet new challenges.

Goldspiel BR, DeChristoforo R, Hoffman JM.

Am J Health Syst Pharm. 2015 Apr 15;72(8):668-9. doi: 10.2146/sp150004. Review. No abstract available.

PMID:
25825190
10.

Integrating pharmacogenetic information and clinical decision support into the electronic health record.

Goldspiel BR, Flegel WA, DiPatrizio G, Sissung T, Adams SD, Penzak SR, Biesecker LG, Fleisher TA, Patel JJ, Herion D, Figg WD, Lertora JJ, McKeeby JW.

J Am Med Inform Assoc. 2014 May-Jun;21(3):522-8. doi: 10.1136/amiajnl-2013-001873. Epub 2013 Dec 3.

11.

Assays for biological agents--author's reply.

Goldspiel JT, Goldspiel BR, Grimes G, Yuan P, Potti G.

Am J Health Syst Pharm. 2013 Jul 1;70(13):1102. doi: 10.2146/130211. No abstract available.

PMID:
23784156
12.

Stability of alemtuzumab solutions at room temperature.

Goldspiel JT, Goldspiel BR, Grimes GJ, Yuan P, Potti G.

Am J Health Syst Pharm. 2013 Mar 1;70(5):439-42. doi: 10.2146/ajhp110632.

13.

Oncology pharmacy practice as a model for international collaborations.

Goldspiel BR.

Am J Health Syst Pharm. 2012 Jun 1;69(11):951-7. doi: 10.2146/ajhp110739. No abstract available.

PMID:
22610027
14.

Improving adherence to research protocol drug exclusions using a clinical alerting system.

Cimino JJ, Farnum L, DiPatrizio GE, Goldspiel BR.

AMIA Annu Symp Proc. 2011;2011:257-66. Epub 2011 Oct 22.

15.

The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone.

Kerkar SP, Kemp CD, Duffy A, Kammula US, Schrump DS, Kwong KF, Quezado M, Goldspiel BR, Venkatesan A, Berger A, Walker M, Toomey MA, Steinberg SM, Giaccone G, Rosenberg SA, Avital I.

Trials. 2009 Dec 23;10:121. doi: 10.1186/1745-6215-10-121.

16.

A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine.

Abraham J, Edgerly M, Wilson R, Chen C, Rutt A, Bakke S, Robey R, Dwyer A, Goldspiel B, Balis F, Van Tellingen O, Bates SE, Fojo T.

Clin Cancer Res. 2009 May 15;15(10):3574-82. doi: 10.1158/1078-0432.CCR-08-0938. Epub 2009 May 5.

17.

Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.

Grandinetti CA, Goldspiel BR.

Pharmacotherapy. 2007 Aug;27(8):1125-44. Review.

PMID:
17655513
18.

Comment on ASCO-ESMO consensus statement on quality cancer care.

Goldspiel B, Wiernikowski J.

J Clin Oncol. 2006 Dec 10;24(35):5613-4; author reply 5614. No abstract available.

PMID:
17158550
19.

Chemotherapy dose density in early-stage breast cancer and non-Hodgkin's lymphoma.

Goldspiel BR.

Pharmacotherapy. 2004 Oct;24(10):1347-57. Review.

PMID:
15628832
20.

A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma.

Bates SE, Bakke S, Kang M, Robey RW, Zhai S, Thambi P, Chen CC, Patil S, Smith T, Steinberg SM, Merino M, Goldspiel B, Meadows B, Stein WD, Choyke P, Balis F, Figg WD, Fojo T.

Clin Cancer Res. 2004 Jul 15;10(14):4724-33.

21.

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.

Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE.

Clin Cancer Res. 2002 Mar;8(3):718-28.

22.

A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).

Bates S, Kang M, Meadows B, Bakke S, Choyke P, Merino M, Goldspiel B, Chico I, Smith T, Chen C, Robey R, Bergan R, Figg WD, Fojo T.

Cancer. 2001 Sep 15;92(6):1577-90.

PMID:
11745237
23.

A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction.

Kohn EC, Reed E, Sarosy GA, Minasian L, Bauer KS, Bostick-Bruton F, Kulpa V, Fuse E, Tompkins A, Noone M, Goldspiel B, Pluda J, Figg WD, Liotta LA.

Clin Cancer Res. 2001 Jun;7(6):1600-9.

24.

Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide phosphate in 0.9% sodium chloride injection.

Yuan P, Grimes GJ, Shankman SE, Daniels CE, Goldspiel BR, Potti GK.

Am J Health Syst Pharm. 2001 Apr 1;58(7):594-8. No abstract available.

PMID:
11296609
25.

Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.

Chico I, Kang MH, Bergan R, Abraham J, Bakke S, Meadows B, Rutt A, Robey R, Choyke P, Merino M, Goldspiel B, Smith T, Steinberg S, Figg WD, Fojo T, Bates S.

J Clin Oncol. 2001 Feb 1;19(3):832-42.

PMID:
11157037
26.

A continuous-improvement approach for reducing the number of chemotherapy-related medication errors.

Goldspiel BR, DeChristoforo R, Daniels CE.

Am J Health Syst Pharm. 2000 Dec 15;57 Suppl 4:S4-9.

PMID:
11148943
27.

Policy decisions about the human genome.

Allen W, Goldspiel B, Kirchdoerfer LJ.

J Am Pharm Assoc (Wash). 2000 Sep-Oct;40(5 Suppl 1):S62-3.

PMID:
11029874
28.

Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer.

Conley B, O'Shaughnessy J, Prindiville S, Lawrence J, Chow C, Jones E, Merino MJ, Kaiser-Kupfer MI, Caruso RC, Podgor M, Goldspiel B, Venzon D, Danforth D, Wu S, Noone M, Goldstein J, Cowan KH, Zujewski J.

J Clin Oncol. 2000 Jan;18(2):275-83.

PMID:
10637240
29.

A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors.

Grem JL, Sorensen JM, Cullen E, Takimoto CH, Steinberg SM, Chen AP, Hamilton JM, Arbuck SG, McAtee N, Lawrence D, Goldspiel B, Johnston PG, Allegra CJ.

Clin Cancer Res. 1999 Sep;5(9):2381-91.

30.

Paclitaxel compatibility with ethylene vinyl acetate bags.

Goldspiel BR.

Ann Pharmacother. 1999 Jul-Aug;33(7-8):873-4. No abstract available.

PMID:
10466923
31.

Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients.

Cowan KH, Moscow JA, Huang H, Zujewski JA, O'Shaughnessy J, Sorrentino B, Hines K, Carter C, Schneider E, Cusack G, Noone M, Dunbar C, Steinberg S, Wilson W, Goldspiel B, Read EJ, Leitman SF, McDonagh K, Chow C, Abati A, Chiang Y, Chang YN, Gottesman MM, Pastan I, Nienhuis A.

Clin Cancer Res. 1999 Jul;5(7):1619-28.

32.

Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy.

Moscow JA, Huang H, Carter C, Hines K, Zujewski J, Cusack G, Chow C, Venzon D, Sorrentino B, Chiang Y, Goldspiel B, Leitman S, Read EJ, Abati A, Gottesman MM, Pastan I, Sellers S, Dunbar C, Cowan KH.

Blood. 1999 Jul 1;94(1):52-61.

PMID:
10381498
33.

Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide in 0.9% sodium chloride injection.

Wolfe JL, Thoma LA, Du C, Goldspiel BR, Gallelli JF, Grimes GJ, Potti GK.

Am J Health Syst Pharm. 1999 May 15;56(10):985-9. No abstract available.

PMID:
10365723
34.

A review of paclitaxel (Taxol) administration, stability, and compatibility issues.

Boyle DA, Goldspiel BR.

Clin J Oncol Nurs. 1998 Oct;2(4):141-5. Review.

PMID:
10232160
35.

Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer.

Herscher LL, Hahn SM, Kroog G, Pass H, Temeck B, Goldspiel B, Cook J, Mitchell JB, Liebmann J.

J Clin Oncol. 1998 Feb;16(2):635-41.

PMID:
9469352
36.

Standardizing the expression and nomenclature of cancer treatment regimens. American Society of Health-System Pharmacist (ASHP), American Medical Association (AMA), American Nurses Association (ANA).

Kohler DR, Montello MJ, Green L, Huntley C, High JL, Fallavollita A Jr, Goldspiel BR.

Am J Health Syst Pharm. 1998 Jan 15;55(2):137-44.

PMID:
9465977
37.

Clinical overview of the taxanes.

Goldspiel BR.

Pharmacotherapy. 1997 Sep-Oct;17(5 Pt 2):110S-125S. Review.

PMID:
9322878
38.

A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies.

Tolcher AW, O'Shaughnessy JA, Weiss RB, Zujewski J, Myhand RC, Schneider E, Hakim F, Gress R, Goldspiel B, Noone MH, Brewster LR, Gossard MR, Cowan KH.

Clin Cancer Res. 1997 May;3(5):755-60.

39.

A phase I study of paclitaxel and cyclophosphamide in recurrent adenocarcinoma of the ovary.

Reed E, Sarosy G, Kohn E, Christian M, Link CJ Jr, Goldspiel B, Davis P, Jacob J, Maher M.

Gynecol Oncol. 1996 Jun;61(3):349-53.

PMID:
8641614
40.

Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer.

Tolcher AW, Cowan KH, Solomon D, Ognibene F, Goldspiel B, Chang R, Noone MH, Denicoff AM, Barnes CS, Gossard MR, Fetsch PA, Berg SL, Balis FM, Venzon DJ, O'Shaughnessy JA.

J Clin Oncol. 1996 Apr;14(4):1173-84.

PMID:
8648372
41.

Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancer.

O'Shaughnessy JA, Tolcher A, Riseberg D, Venzon D, Zujewski J, Noone M, Gossard M, Danforth D, Jacobson J, Chang V, Goldspiel B, Keegan P, Giusti R, Cowan KH.

Blood. 1996 Mar 15;87(6):2205-11.

PMID:
8630380
42.

Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer.

Fisherman JS, Cowan KH, Noone M, Denicoff A, Berg S, Poplack D, Balis F, Venzon D, McCabe M, Goldspiel B, Chow C, Ognibene FP, O'Shaughnessy J.

J Clin Oncol. 1996 Mar;14(3):774-82.

PMID:
8622023
43.

Issues in antiemetic therapy.

Goldspiel BR, Curt GA.

Cancer. 1996 Mar 1;77(5):823-6. No abstract available.

PMID:
8608470
44.

Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers.

Kohn EC, Reed E, Sarosy G, Christian M, Link CJ, Cole K, Figg WD, Davis PA, Jacob J, Goldspiel B, Liotta LA.

Cancer Res. 1996 Feb 1;56(3):569-73.

45.

Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients.

Tolcher AW, Cowan KH, Noone MH, Denicoff AM, Kohler DR, Goldspiel BR, Barnes CS, McCabe M, Gossard MR, Zujewski J, O'Shaughnessy JA.

J Clin Oncol. 1996 Jan;14(1):95-102.

PMID:
8558227
46.

A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy.

O'Shaughnessy JA, Venzon DJ, Gossard M, Noone MH, Denicoff A, Tolcher A, Danforth D, Jacobson J, Keegan P, Miller L, Chow C, Goldspiel B, Cowan KH.

Blood. 1995 Oct 15;86(8):2913-21.

PMID:
7579383
47.

Pharmacokinetics of orally administered carboxyamido-triazole, an inhibitor of calcium-mediated signal transduction.

Figg WD, Cole KA, Reed E, Steinberg SM, Piscitelli SC, Davis PA, Soltis MJ, Jacob J, Boudoulas S, Goldspiel B, et al.

Clin Cancer Res. 1995 Aug;1(8):797-803.

48.

Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas.

Wilson WH, Chabner BA, Bryant G, Bates S, Fojo A, Regis J, Jaffe ES, Steinberg SM, Goldspiel BR, Cheson BD, et al.

J Clin Oncol. 1995 Feb;13(2):381-6.

PMID:
7531220
49.

A pilot study of amiodarone with infusional doxorubicin or vinblastine in refractory breast cancer.

Bates SE, Meadows B, Goldspiel BR, Denicoff A, Le TB, Tucker E, Steinberg SM, Elwood LJ.

Cancer Chemother Pharmacol. 1995;35(6):457-63.

PMID:
7882454
50.

A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients.

O'Shaughnessy JA, Denicoff AM, Venzon DJ, Danforth D, Pierce LJ, Frame JN, Bastian A, Ghosh B, Goldspiel B, Miller L, et al.

Ann Oncol. 1994 Oct;5(8):709-16.

PMID:
7826903

Supplemental Content

Loading ...
Support Center